Drug targets for Cancer: PTEN

Drug Targets for Cancer: PTEN and Cancer

Phosphatase and tensin homolog (PTEN) deleted on chromosome 10 is well identified as a tumor suppressor gene and found frequently mutated or deleted in a variety of cancers, such as endometrial cancer, prostate cancer, small-cell lung cancer, etc. For breast cancer, PTEN loss or mutation is found in a percentage of 13%, 24%, and 35% for luminal A, luminal B, and basal-like breast cancers, respectively. Clinically, PTEN loss has been linked to brain metastasis in breast cancer patients. PTEN promoter variations have also been shown to influence breast cancer recurrence and patient survival. Depowski et al also demonstrated that PTEN insufficiency was linked with breast cancer poor prognosis.9 Further, for Her2-positive breast cancer patients with recurrent or metastatic disease, PTEN loss might be a predictor for the resistance of trastuzumab-based salvage treatment. In endometrial cancer, loss of heterozygosity at the PTEN region has been reported in approximately 40% of cases and somatic PTEN mutations have been identified in 37% to 83% of tumors. In animal models PTEN knockout mice develop endometrial cancer precursors and cancer and women with Cowden's disease, who carry germline PTEN mutations, are at elevated risk of endometrial cancer. Accordingly, it is proposed that loss of PTEN function represents an important early event in endometrial carcinogenesis.

Drug Targets for Cancer: PTEN related Products

Drug targets for cancer: PTEN research reagents

Other vital drug targets for cancer likePTEN:

Drug Targets for Cancer: PTEN Related Reference

Chiang K-C, Chen H-Y, Hsu S-Y, et al. PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo. Drug Design, Development and Therapy. 2015;9:4631-4638.
In endometrial cancer, loss of heterozygosity at the PTEN region has been reported in approximately 40% of cases and somatic PTEN mutations have been identified in 37% to 83% of tumors. In animal models PTEN knockout mice develop endometrial cancer precursors and cancer and women with Cowden's disease, who carry germline PTEN mutations, are at elevated risk of endometrial cancer. Accordingly, it is proposed that loss of PTEN function represents an important early event in endometrial carcinogenesis.
Spinelli L, Lindsay Y E, Leslie N R. PTEN inhibitors: an evaluation of current compounds[J]. Advances in biological regulation, 2015, 57: 102-111.

Drug Targets for Cancer: PTEN Related Information

Drug Targets for Cancer